TAR-210 is an intravesical targeted releasing system designed to provide sustained, local release of erdafitinib into the bladder. Every week, our Whisper Index uncovers five overlooked stocks with ...

On Tuesday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson's (NYSE:JNJ) Inlexzo (gemcitabine intravesical system) as a new treatment approach for certain types of bladder ...

Johnson & Johnson is ending one of several studies of a proposed bladder cancer therapy, but the pharmaceutical giant said it remains confident in the drug's prospects. J&J said it stopped a Phase 3 ...

TAR-200 monotherapy shows highest complete response with sustained benefits in 12-month data from Phase 2b SunRISe-1 study (Cohort 2) Compelling first results from Cohort 4 of Phase 2b SunRISe-1 study ...

(RTTNews) - Johnson & Johnson (JNJ) Monday announced that it is set to present pivotal data from its oncology pipeline at the American Urological Association or AUA 2025 Annual Meeting in Las Vegas, ...

RARITAN, N.J., July 17, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) granted Priority Review to the New Drug Application (NDA) ...

The FDA has signed off on Johnson & Johnson’s highly anticipated bladder cancer drug Inlexzo, marking an advance in the ability to care for patients who otherwise face bladder removal and limited ...

Renal Cell Carcinoma of Variant Histology: New Biologic Understanding Leads to Therapeutic Advances Urothelial cancer (UC) is the most common histology seen in bladder tumors. The 2022 WHO ...

There’s a new twist in the fight against bladder cancer — and it’s delivering game-changing results. In a recent clinical trial, a pretzel-shaped device that slowly releases chemotherapy drugs ...